

2021 Annual General Meeting

PYC Therapeutics (ASX:PYC) (**PYC** or the **Company**) advises that the Annual General Meeting of the Company (**AGM**) will be held on 18 November 2021 at 9.00am AWST.

The AGM will be held at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia.

Please see attached a Notice of Annual General Meeting and a letter to shareholders advising further details of the meeting and accessing meeting documents.

This announcement has been approved for release by the Board of PYC Therapeutics Limited

For further information, please contact:

Kevin Hart

Company Secretary

+61 8 9316 9100

info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and the Company's preclinical, clinical, regulatory and corporate operations are based in San Diego, California. For more information, visit pyctx.com, or follow us on [LinkedIn](#) and [Twitter](#).

CONTACTS:

INVESTORS

Deborah Elson/Matthew DeYoung
Argot Partners
deborah@argotpartners.com
matthew@argotpartners.com

MEDIA

Leo Vartorella
Argot Partners
leo@argotpartners.com



18 October 2021

2021 Annual General Meeting

Dear Shareholder,

PYC Therapeutics (ASX:PYC) (**PYC** or the **Company**) advises that the Annual General Meeting of the Company (**AGM**) will be held on 18 November 2021 at 9.00am AWST.

The AGM will be held at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia.

Further to the temporary modifications to the Corporation Act introduced by the Commonwealth Treasurer, the Company will not be sending hard copies of the Notice of Meeting for the AGM (**Notice**) to shareholders.

The Notice can be viewed and downloaded from the Company's website at www.pyctx.com.

It is currently the intention of the Board to hold a physical meeting for shareholders to attend. However, with the continuing developments surrounding COVID-19, the Directors encourage all Shareholders to vote by lodging the proxy form attached to the Notice rather than attend the meeting.

The Board will continue to monitor Australian Government restrictions on public gatherings. If it becomes necessary or appropriate to make alternative arrangements for the AGM such as via a virtual meeting, the Company will notify shareholders accordingly via the Company's website at www.pyctx.com and the ASX announcement platform.

Regards

A handwritten signature in black ink, appearing to be "Kevin Hart", written over a horizontal line.

Kevin Hart

Company Secretary



PYC Therapeutics Limited
ACN 098 391 961

Notice of Annual General Meeting

THIS IS AN IMPORTANT DOCUMENT AND REQUIRES YOUR ATTENTION

If you are in any doubt as to the contents of this document or how to deal with it, please consult your financial or other professional adviser.

The annual general meeting will be held:

- at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia
- on Thursday, 18 November 2021 at 9.00am AWST

The Company is taking precautions to facilitate an in-person meeting in accordance with COVID-19 restrictions. If the situation in relation to COVID-19 changes in a way affecting the ability to facilitate an in-person meeting, the Company will provide an update ahead of the meeting by way of an ASX announcement.

You can vote by:

- attending and voting at the meeting; or
- appointing someone as your proxy to attend and vote at the meeting on your behalf, by completing and returning the Proxy Form to the Company in the manner set out in the Proxy Form accompanying this Notice.

PYC Therapeutics Limited
ACN 098 391 961
(Company)

Notice of Annual General Meeting

Notice is given that the annual general meeting of PYC Therapeutics Limited will be held at the Auditorium in The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia on Thursday, 18 November 2021 at 9.00 am AWST.

An Explanatory Statement containing information on each of the following Resolutions accompanies this Notice. The Explanatory Statement (including the Annexure) and the Proxy Form forms part of this Notice.

Terms used in this Notice are defined in the Schedule.

Agenda

1 Annual Report

To receive and consider the annual financial report of the Company for the financial year ended 30 June 2021 which includes the Financial Report, Directors' Report and Auditor's Report.

2 Resolutions

Resolution 1: Remuneration Report

To consider and, if thought fit, pass the following as an ordinary resolution:

That the Remuneration Report for the year ended 30 June 2021 be adopted by the Company.

Note: Votes on this Resolution are advisory only and do not bind the Directors or the Company. A voting exclusion applies to this Resolution (see the Explanatory Statement).

Resolution 2: Re-Election of Mr. Alan Tribe

To consider and, if thought fit, pass the following as an ordinary resolution:

"That Mr. Alan Tribe be re-elected as a Director."

Resolution 3: Re-Election of Dr Michael Rosenblatt

To consider and, if thought fit, pass the following as an ordinary resolution:

"That Dr. Michael Rosenblatt be re-elected as a Director."

Resolution 4: Re-Election of Mr. Jason Haddock

To consider and, if thought fit, pass the following as an ordinary resolution:

“That Mr. Jason Haddock be re-elected as a Director.”

Resolution 5: Approval of change of Auditor

To consider and, if thought fit, pass the following as an ordinary resolution:

That for the purposes of section 327B(1)(b) of the Corporations Act 2001 (Cth) and for all other purposes, PriceWaterhouseCoopers, having been nominated by a shareholder and having consented in writing to act as auditors of the Company, be appointed as auditors of the Company.

By order of the Board

Kevin Hart
Company Secretary
PYC Therapeutics Limited

Date: 18 October 2021

PYC Therapeutics Limited
ACN 098 391 961
(Company)

Explanatory Statement

1. Introduction

This Explanatory Statement has been prepared for the information of Shareholders in connection with the business to be conducted at the Meeting. The Explanatory Statement forms part of the Notice which should be read in its entirety.

2. Action to be taken by Shareholders

Shareholders should read the Notice including the Explanatory Statement carefully before deciding how to vote on the Resolutions.

1.1 Voting entitlement

The Directors have determined pursuant to Regulation 7.11.37 of the Corporations *Regulations 2001* (Cth) that the persons eligible to vote at the Meeting are those who are registered Shareholders at 4.00pm AWST on Tuesday, 16 November 2021.

1.2 Voting in person

Due to the COVID-19 pandemic, the Company may be bound to adhere to any government restrictions on gatherings in place at the date of the Meeting. This could result in the number of people attending the Meeting being restricted. Although the Company intends for all attendees access to the Meeting, should numbers need to be restricted, Shareholders will be given priority.

The Company intends to monitor government guidelines in the lead up to the Meeting, and, if deemed necessary, may change the way in which shareholders can attend and vote on the day of the Meeting, which may include the use of virtual meeting technology. If such an arrangement is required, the Company will release an announcement to the ASX advising of such arrangements.

1.3 Voting by proxy

A Proxy Form is located at the end of the Explanatory Statement.

To vote by proxy, please use one of the following methods:

Online	visiting https://investor.automic.com.au/#/loginsah or by scanning the QR code, found on the Proxy Form with your mobile device
By post	Automic Group, GPO Box 5193, Sydney NSW 2001
By hand	Automic, Level 5, 126 Phillip Street, Sydney NSW 2000

Your Proxy instruction must be received not later than 48 hours before the commencement of the Meeting. **Proxy Forms received later than this time will be invalid.**

1.4 **Power of Attorney**

If the Proxy Form is signed under a power of attorney on behalf of a Shareholder, then the attorney must make sure that either the original power of attorney or a certified copy is sent with the proxy form, unless the power of attorney has already provided it to the Registry.

1.5 **Corporate Representatives**

If a representative of a corporate shareholder or a corporate proxy will be attending the Meeting, the representative should bring to the Meeting adequate evidence of their appointment, unless this has previously been provided to the Registry.

1.6 **Chair's voting intentions**

The Chair intends to exercise all available proxies in favour of all Resolutions, unless the Shareholder has expressly indicated a different voting intention.

If the Chair is your proxy, either by appointment or by default, and you have not indicated your voting intention, you expressly authorise the Chair to exercise the proxy in respect of Resolution 1 even though these Resolutions are connected directly or indirectly with the remuneration of the Company's Key Management Personnel.

2. **Annual Report**

The Corporations Act requires the Company's Financial Report, Directors' Report and Auditors Report for the last financial year to be presented to the Annual General Meeting. The Financial Report, Directors' Report and Auditor's Report are contained in the 2021 Annual Report.

The Annual Report is available from the Company's website at www.pyctx.com

While no resolution is required in relation to this item, Shareholders will be given the opportunity to ask questions and make comments on the Annual Report.

The Company's Auditor will be present at the Meeting and Shareholders will have an opportunity ask the auditor questions about the conduct of the audit and the preparation and content of the Auditor's Report.

3. **Resolution 1: Adoption of Remuneration Report**

3.1 **Background**

The Corporations Act requires a resolution that the adoption of the Company's Remuneration Report be put to a vote at the Annual General Meeting.

The Remuneration Report explains the Board's policies in relation to the nature and level of remuneration paid to the Key Management Personnel (including the Directors), sets out details of the remuneration and service agreements for each member of Key Management Personnel and sets out the details of any share-based compensation.

An opportunity will be given to Shareholders as a whole, to ask questions about, or make comments on, the Remuneration Report. The Remuneration Report is set out in the Annual Report which is available online at www.pyctx.com

Resolution 1 is advisory only and does not bind the Directors or the Company. However, the Board will take the outcome of the vote very seriously when considering the Company's future remuneration policy.

3.2 **Voting exclusion statement**

The Company will disregard any votes cast on Resolution 1:

- (a) by or on behalf of a member of the Key Management Personnel whose remuneration details are included in the Remuneration Report or their Closely Related Parties (regardless of the capacity in which the vote is cast); or
- (b) as proxy by a person who is a member of the Key Management Personnel on the date of the Meeting or their Closely Related Parties.

However, votes will not be disregarded if they are cast as proxy for a person entitled to vote on Resolution 1:

- (c) in accordance with a direction on the Proxy Form; or
- (d) by the person chairing the Meeting, in accordance with an express authorisation in the Proxy Form to exercise the proxy even though the Resolution is connected with the remuneration of the Key Management Personnel.

3.3 **Recommendation**

The Board recommends that Shareholders vote in favour of Resolution 1.

4. **Re-Election of Directors**

Resolutions 2, 3 and 4 seek approval for the re-election of Mr Alan Tribe, Dr Michael Rosenblatt and Mr Jason Haddock as Directors.

4.1 **Resolution 2: Re-Election of Mr Alan Tribe**

Mr Alan Tribe is the Company's Non-Executive Chair. Mr Tribe was first appointed to the Board on 10 April 2018 and was last re-elected on 21 November 2019 at the 2019 AGM.

Mr Tribe retires as a Director by way of rotation pursuant to Rule 20.6 of the Constitution at the conclusion of the Meeting. Mr Alan Tribe offers himself, and is eligible for, re-election at this Meeting.

If Resolution 2 is passed, Mr Tribe will be re-elected as Non-Executive Chair of the Company. If Mr Alan Tribe is not re-elected, Mr Tribe will retire as a Director. The Board may consider an alternative Director be appointed, with ratification at the Company's next AGM.

4.2 **Resolutions 3 and 4: Re-Election of Dr Michael Rosenblatt and Mr Jason Haddock**

Rule 20.3 of the Constitution allows the Board to appoint at any time a person to be a Director. Any Director so appointed automatically retires at the next annual general meeting and is then eligible for re-election. ASX Listing Rule 14.4 also provides that each additional director appointed during the year is to hold office until the next annual general meeting and is then eligible for election as a Director of the Company.

Dr Michael Rosenblatt

Dr Rosenblatt was appointed by the Board as a Non-Executive Director on 17 March 2021. Dr Rosenblatt automatically retires from office at the end of the Meeting in accordance with Rules 20.3 and 20.8 of the Constitution.

Dr Rosenblatt offers himself, and is eligible for, re-election at this Meeting.

If Resolution 3 is passed, Dr Rosenblatt will be re-elected as a Non-Executive Director. If Resolution 3 is not passed, Dr Rosenblatt will not be a Director of the Company. The Board may consider an alternative Director be appointed, with ratification at the Company's next AGM.

Jason Haddock

Jason Haddock was appointed by the Board as a Non-Executive Director on 29 March 2021. Mr Haddock automatically retires from office at the end of the Meeting in accordance with Rules 20.3 and 20.8 of the Constitution.

Mr Haddock offers himself, and is eligible for, re-election at this Meeting.

If Resolution 4 is passed, Mr Haddock will be re-elected as a Non-Executive Director. If Resolution 3 is not passed, Mr Haddock will not be a Director of the Company. The Board may consider an alternative Director be appointed, with ratification at the Company's next AGM.

Sahm Nasser

Sahm Nasser was appointed as a Director on 10 December 2020 under Rule 20.3 of the Constitution. Mr Nasser automatically retires from office at the end of the Meeting in accordance with Rules 20.3 and 20.8 of the Constitution. Mr Nasser has not offered himself for re-election and will cease to be a Director at the end of the Meeting.

4.3 Profiles

Mr. Alan Tribe

Mr Tribe has a background in the accounting profession both in the UK and Australia. Moving into industry, he became the Managing Director of a group of companies with interests in natural resources in Australia and overseas. The group also included a technology company which grew through both successful product development and acquisitions.

He was closely involved in establishing subsidiary operations in the USA, UK and Singapore to access markets worldwide.

Most recently he was the catalyst for the development of large retail operations in Western and South Australia.

Mr Tribe will contribute his broad experience in successfully commercialising technology internationally. He represents a large shareholding in the Company of approximately 30.93%.

Mr Tribe has held no other Australian listed company directorships in the last three years.

Mr Alan Tribe is not considered an independent Director due to his substantial shareholding in the Company.

Dr Rosenblatt

Dr Rosenblatt is currently a Senior Partner of Flagship Pioneering.

Dr Rosenblatt joined Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer from 2009 to 2016. During an earlier period at Merck, he led drug discovery efforts in ophthalmology, molecular biology, bone biology, virology, cancer research, gastroenterology, lipid metabolism and cardiovascular research.

He has held appointments as Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; President, Harvard Faculty Dean and Senior Vice President for Academic Programs of Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology.

Dr Rosenblatt has served as a founding scientist, scientific advisory board member or director of more than 12 biopharmaceutical companies. He received his BA summa cum laude from Columbia University and his MD magna cum laude from Harvard Medical School, and completed internship, residency and endocrinology training at the Massachusetts General Hospital.

Dr Rosenblatt has held no other Australian listed company directorships in the last three years.

If elected, Dr Rosenblatt is considered to be an independent Director. Dr Rosenblatt is not considered by the Board to hold any interest, position or relationship that might influence, or reasonably be perceived to influence, in a material respect his capacity to bring an independent judgement to bear on issues before the Board and to act in the best interests of the entity as a whole rather than in the interests of an individual security holder or other party.

Mr Jason Haddock

Jason Haddock has more than 20 years of financial and operational experience in the biopharmaceutical industry and currently serves as a Board Director of Codiak Biosciences, a biotech company developing precision exosome therapeutics. He served as CFO at Array BioPharma, Inc., where he was instrumental in the execution of an oncology-focused research, development and commercialization strategy that culminated in the successful launch of two new drugs and the company ultimately being acquired by Pfizer.

Prior, he worked at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. Mr. Haddock has also served as CFO for ArcherDX as the company was acquired by Invitae to create a global leader in comprehensive cancer genetics and precision oncology. He holds a BS in accounting from Illinois State University and an EMBA from Washington University in St. Louis.

Mr Haddock has held no other Australian listed company directorships in the last three years.

If elected, Mr Haddock is considered to be an independent Director. Mr Haddock is not considered by the Board to hold any interest, position or relationship that might influence, or reasonably be perceived to influence, in a material respect his capacity to bring an independent judgement to bear on issues before the Board and to act in the best interests of the entity as a whole rather than in the interests of an individual security holder or other party.

4.4 **Recommendations**

The Board (other than Mr Tribe) recommends that Shareholders vote in favour of Resolution 2. Mr Tribe makes no recommendation in respect of Resolution 2.

The Board (other than Dr Rosenblatt) recommends that Shareholders vote in favour of Resolution 3. Dr Rosenblatt makes no recommendation in respect of Resolution 3.

The Board (other than Mr Haddock) recommends that Shareholders vote in favour of Resolution 4. Mr Haddock makes no recommendation in respect of Resolution 4.

5. **Resolution 5: Approval of change of Auditor**

5.1 **Background**

As announced to ASX on 1 July 2021, the Board appointed PriceWaterhouseCoopers (**PwC**) as the new auditor of the Company to fill the casual vacancy following the resignation of the previous auditor of the Company, HLB Mann Judd. In accordance with section 327C(2) of the Corporations Act, the appointment continues only until this Meeting.

The Board have appointed PwC for the financial year ending 30 June 2021 and subsequent financial years based on PwC's global expertise and certifications.

Section 327B of the Corporations Act requires the Company to confirm the appointment of PwC as auditor by obtaining shareholder approval by ordinary resolution.

The Board supports the appointment of PwC as the Company's auditor.

In accordance with the section 328B(1) of the Corporations Act, a member of the Company, Australian Land Pty Ltd (a company associated with Director, Mr Alan Tribe), has given the Company written notice of the nomination of PwC for appointment as auditor. A copy of the nomination is attached to this Notice as Annexure A. PwC has consented in writing to the appointment as the Company's auditor and, as at the date of this Notice, has not withdrawn its consent.

If Resolution 5 is passed, the appointment of PwC as the Company's auditor will take effect from the conclusion of the Meeting.

If Resolution 5 is not passed, there will be a vacancy in respect of the Company's auditor, which the Directors will be obliged to fill within one month, in accordance with section 327C of the Corporations Act.

5.2 **Recommendation**

The Board recommends that Shareholders vote in favour of Resolution 5.

Schedule – Definitions

In this Notice:

AWST	means Australian Western Standard Time.
Annual Report	means the Directors' Report, the Financial Report and the Auditor's Report in respect to the financial year ended 2021.
ASX	means ASX Limited ACN 008 624 691.
Auditor's Report	means the auditor's report on the Financial Report.
Auditor	means PriceWaterhouseCoopers.
Board	means the board of Directors.
Closely Related Party	means: (a) a spouse or child of the member; or (b) has the meaning given in section 9 of the Corporations Act.
Company or PYC	means PYC Therapeutics Limited ACN 098 391 961.
Constitution	means the constitution of the Company as at the commencement of the Meeting.
Corporations Act	means the <i>Corporations Act 2001</i> (Cth).
Director	means a director of the Company.
Directors' Report	means the annual directors' report prepared under chapter 2M of the Corporations Act for the Company and its controlled entities.
Explanatory Statement	means the Explanatory Statement attached to the Notice.
Financial Report	means the annual financial report prepared under Chapter 2M of the Corporations Act of the Company and its controlled entities.
Key Management Personnel or KMP	has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any Director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.
Listing Rules	means the listing rules of ASX.
Meeting	means the Annual General Meeting convened by the Notice.

Notice	means this notice of Meeting.
Remuneration Report	means the remuneration report of the Company contained in the Directors' Report.
Registry	means Atomic Group, the Company's Registry.
Resolutions	means a resolution proposed to be considered and, if thought fit, to be passed at the Meeting.
Shareholder	means a shareholder of the Company.

Annexure A Nomination for PwC to be re-appointed as auditor

To: PYC Therapeutics Limited
 Suite 8, 7 The Esplanade
 Mt Pleasant Western Australia 6153

Dear Company Secretary

Nomination of Auditor

As a member of PYC Therapeutics Limited ACN 098 391 961 (**Company**), and pursuant to section 328B(1) of the *Corporations Act 2001* (Cth), I nominate PriceWaterhouseCoopers of Level 15, 125 St Georges Terrace, Perth Western Australia 6000 to be appointed as the auditor of the Company at the Annual General Meeting to be held on 18 November 2021, or at any adjustment or postponement of that meeting.

Date: 4 May 2021

Signed:



Alan Tribe
Director
Australian Land Pty Ltd

If you are attending the meeting in person, please bring this with you for Securityholder registration.

Holder Number:

Your proxy voting instruction must be received by **9.00am (AWST) on Tuesday 16 November 2021**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY VOTE ONLINE

Vote online at <https://investor.automic.com.au/#/loginsah>



Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting form.

- ✓ **Save Money:** help minimise unnecessary print and mail costs for the Company.
- ✓ **It's Quick and Secure:** provides you with greater privacy, eliminates any postal delays and the risk of potentially getting lost in transit.
- ✓ **Receive Vote Confirmation:** instant confirmation that your vote has been processed. It also allows you to amend your vote if required.

SUBMIT YOUR PROXY VOTE BY PAPER

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 – APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of KMP.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automic.com.au>.

